{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:09:10Z","timestamp":1782248950368,"version":"3.54.5"},"reference-count":58,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T00:00:00Z","timestamp":1285545600000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, Janicak PG, Sweeney JA. Double\u2010blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010: 12: 593\u2013605. \u00a9 2010 The Authors. Journal compilation \u00a9 2010 John Wiley &amp; Sons A\/S.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To determine the relative effects of risperidone and divalproex in pediatric mania.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    This is a double\u2010blind, randomized, outpatient clinical trial with 66 children and adolescents (mean age\u2003=\u200310.9\u2003\u00b1\u20033.3\u2003years; age range\u2003=\u20038\u201318\u2003years) with mania who were randomly assigned to either risperidone (0.5\u20132\u2003mg\/day, n\u2003=\u200333) or divalproex (60\u2013120\u2003\u03bcg\/mL, n\u2003=\u200333) for a six\u2010week period. Measures included the Young Mania Rating Scale (YMRS) and Child Depression Rating Scale\u2010Revised (CDRS\u2010R).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Mixed\u2010effects regression models, with interaction between time and the active drug as predictors, found that the risperidone group had more rapid improvement than the divalproex group (p\u2003&lt;\u20030.05), although final scores did not differ significantly between groups. Mixed models using only those subjects who completed the six\u2010week study found similar results. The response rate on YMRS was 78.1% for risperidone and 45.5% for divalproex (p\u2003&lt;\u20030.01). The remission rate for risperidone was 62.5%, compared with 33.3% for divalproex (p\u2003&lt;\u20030.05). Improvement on the CDRS\u2010R was significantly higher for the risperidone group relative to the divalproex group (p\u2003&lt;\u20030.05). There were no significant differences between groups in safety, but subject retention was significantly higher at study endpoint in the risperidone group (p\u2003&lt;\u20030.01). Dropout rate was 24% in the risperidone group and 48% in the divalproex group, with increased irritability being the most common reason for dropout in the latter. There was no significant weight gain in either group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    Results suggest that risperidone was associated with more rapid improvement and greater reduction in manic symptoms compared to divalproex. Although the results suggest that both drugs are safe, risperidone\u2019s lower attrition rate and lower rate of adverse events may suggest better toleration. Clinical trials with larger samples are required to confirm these preliminary findings.\n                  <\/jats:p>","DOI":"10.1111\/j.1399-5618.2010.00850.x","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T05:24:06Z","timestamp":1285565046000},"page":"593-605","source":"Crossref","is-referenced-by-count":73,"title":["Double\u2010blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder"],"prefix":"10.1111","volume":"12","author":[{"given":"Mani N","family":"Pavuluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Parnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Carbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Janicak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.01.022"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.10.1125"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.10.070"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.240"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(03)00052-9"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200503000-00006"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000242240.69678.c4"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721120-00005"},{"key":"e_1_2_7_10_2","unstructured":"ChangK NyilasM AurangC.Efficacy of aripiprazole in children (10\u201317\u2003years old) with mania. Presented at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Boston MA USA October 23\u201328 2007."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000194567.63289.97"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200006000-00009"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb09994.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199504000-00006"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00204.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00012"},{"key":"e_1_2_7_18_2","unstructured":"SegalS.A double\u2010blind placebo\u2010controlled trial to evaluate the safety and efficacy of depakote ER for the treatment of mania associated with bipolar disorder in children and adolescents 2006. Available at:http:\/\/www.clinicalstudyresults.org\/drugdetails\/?company_id=1&sort=c.company_name&page=1&drug_id=1561; last accessed 3 August 2010."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.665"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0519"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.7.1179"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000159151.75345.20"},{"key":"e_1_2_7_24_2","unstructured":"KowatchRA FindlingR SchefferR StanfordKE.Placebo controlled trial of divalproex versus lithium for bipolar disorder. Presented at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Boston MA USA October 23\u201328 2007."},{"key":"e_1_2_7_25_2","unstructured":"PandinaG DelBelloM KushnerSet\u00a0al.Risperidone for the treatment of acute mania in bipolar youth. Presented at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Boston MA USA October 23\u201328 2007."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.019"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.311"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.05.017"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00176-1"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00011"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.1.35"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750143500"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000205700.40700.50"},{"key":"e_1_2_7_35_2","volume-title":"Assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.336"},{"key":"e_1_2_7_39_2","first-page":"331","volume-title":"Statistical Issues in Drug Research and Development","author":"Fisher LD","year":"1990"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1057"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1113"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000320115.38434.16"},{"issue":"1","key":"e_1_2_7_43_2","first-page":"S122","article-title":"Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia or schizoaffective disorder","volume":"30","author":"Versavel M","year":"2005","journal-title":"Neuropsychopharmacol"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e31819c55ec"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360044034"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04960yel"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649101"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(06)00132-9"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00159-5"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00128-2"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7348.1278"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00750.x"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05164yel"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0520"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.008"},{"issue":"4","key":"e_1_2_7_59_2","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll CU","year":"2008","journal-title":"J Clin Psychiatry"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2010.00850.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2010.00850.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:39:31Z","timestamp":1698698371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2010.00850.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1399-5618.2010.00850.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2010.00850.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.5770968.5753068","asserted-by":"object"}]},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}